CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, announced that encouraging clinical findings were reported today at the American Society of Hematology (ASH) 49th Annual Meeting and Exposition with IMGN901 (huN901-DM1) and AVE1642.
